Condition: Metastatic Microsatellite Stable Colorectal Carcinoma · Refractory Microsatellite Stable Colorectal Carcinoma · Stage IV Colorectal Cancer AJCC v8 · Sponsor: National Cancer Institute (NCI)
This phase I trial tests the safety, side effects, and best dose of abemaciclib in combination with 5-fluorouracil and how well it works in treating patients with colorectal cancer that has spread from where it first started (primary site) to other places in the body (metastatic) and that has not responded to treatment (refractory). Abemaciclib, a type of cyclin-dependent kinase inhibitor, blocks certain proteins, which may help keep tumor cells from growing. 5-fluorouracil, a type of antimetabolite, stops cells from making deoxyribonucleic acid (DNA) and may kill tumor cells. Giving abemaciclib in combination with 5-fluorouracil may be safe, tolerable, and/or effective in treating patients with metastatic and refractory colorectal cancer.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care | Irvine, California, United States | Recruiting |
| UC Irvine Health/Chao Family Comprehensive Cancer Center | Orange, California, United States | Recruiting |
| Montefiore Medical Center-Einstein Campus | The Bronx, New York, United States | Recruiting |
| Montefiore Medical Center-Weiler Hospital | The Bronx, New York, United States | Recruiting |
| Montefiore Medical Center - Moses Campus | The Bronx, New York, United States | Recruiting |
| University of Cincinnati Cancer Center-UC Medical Center | Cincinnati, Ohio, United States | Recruiting |
| University of Cincinnati Cancer Center-West Chester | West Chester, Ohio, United States | Recruiting |
| University of Pittsburgh Cancer Institute (UPCI) | Pittsburgh, Pennsylvania, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06654037